Follow the Prime Medicine, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €527.4m. The latest transaction was disclosed on 5 August 2025 (Acquisition). Among the most active insiders: GV 2019 GP, L.L.C.. Every trade is openly available.
43
Insider Decl.
n/a
Thresholds
€87m
14 ops.
Buy Volume
€4m
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Prime Medicine, Inc. Buy (bullish), based on 10 analysts. Average price target: US$7.12.
63Σ signal
Buys €87m€4m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Prime Medicine, Inc. es una empresa de biotecnología centrada en el desarrollo de terapias génicas para tratar enfermedades genéticas. Emplea tecnología avanzada para diseñar tratamientos innovadores.